Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term IV ibandronate extension study after BM16550
2004-002570-32Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ibandronic acid in postmenopausal osteoporosis (2 arms), sponsored by Roche. Primary endpoints: Long-term safety and tolerability and Bone histomorphometry. Started Oct 2004; status: completed.
02
Drugs
ibandronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2004-002570-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002570-32.